Following our blog last week about our new custom antibody dataset, today we’re going to look at this data in a little more detail, focusing on the top targets for custom antibodies. Our custom antibody data helps suppliers identify antibodies to license in, but also gives us a great insight to trends in the market. […]
In a first for CiteAb, today we’re taking a first look at the global custom antibody market and we’ll be highlighting those suppliers claiming the largest share. CiteAb founder Dr Andrew Chalmers said: “As you know, we specialise in collating citations for catalogue antibodies, however over the last few months our team has been taking […]
Great news – you’re here using CiteAb and you’re in really good company. A lot of it! The CiteAb user base has grown and grown, and we are now helping over 50,000 users like you to find quality antibodies every month. In addition, we have now got over a million citations listed in the CiteAb […]
Over recent weeks we’ve covered loads of different data stories here on our blog and have given away free data with each of them. We thought it might be helpful to provide a quick recap, and links to help you collect any of the free data sets you might have missed out on. We reported […]
Last week we reported on our brand new text mining technology developed by our team here at CiteAb. Today we’re looking at some very specific data we can access as a result of this new technology – insights into the antibodies used in prostate cancer research. CiteAb developer Matt Helsby said: “Using this new text […]
We recently told you that we have some tech updates in the pipeline – and today we are going to speak to one of our developers, Matt Helsby, to show you a new piece of tech we’ve created. So Matt, what’s new? “Hi there! Today we’re launching an update to our text mining technology which […]
Last week we reported on the continued fast paced growth of the Chinese antibody market, and mentioned that this has not been without its perils. Today we’re going to take a look at the lucrative market for fake research reagents that has arisen in China and was recently exposed by science journal Nature. Nature reports […]
Today we return to our first ever data report, released three years ago, when we claimed that China was a market no supplier could ignore, and we look at new data to see whether our predictions came true. Back in 2014 we stated that ‘the data suggests that China is set to claim the lion’s […]
We’re excited to be welcoming three new people to the CiteAb team – two product managers and a developer. Alicia Cooper and Rebecca Sadler join us as product managers as CiteAb continues to grow and offer ever more complex data sets and market reports. Rebecca graduates from her biology degree at the University of Bath […]
We recently announced that our team here at CiteAb has expanded our platform to cover multiple reagent types, and today we’re taking a first look at some of our new data. The inhibitors and activators used by life scientists to investigate cellular processes are collectively termed as ‘chemical probes’. They provide vital tools for […]
CiteAb is the largest citation-ranked antibody search engine and database. It provides an impartial way to find and compare antibodies that work.
We use our database of antibody publications to produce unique antibody market data, income from this data allows us to remain free to list and impartial.
Publication metadata is provided by PubMed®, a database of the US National Library of Medicine.
PubMed® is a registered trademark of US National Library of Medicine.
Company registered in England #08530854. VAT #179706954.
In partnership with
© CiteAb 2012-2015. All Rights Reserved.